Abstract Activation of the b-adrenergic receptor (bAR) pathway is the main mechanism of the heart to increase cardiac output via protein kinase A (PKA)-mediated phosphorylation of cellular target proteins, and perturbations therein may contribute to cardiac dysfunction in heart failure. In the present study a comprehensive analysis was made of mediators of the bAR pathway, myofilament properties and cardiac structure in patients with idiopathic (IDCM; n = 13) and ischemic (ISHD; n = 10) cardiomyopathy in comparison to non-failing hearts (donor; n = 10) for the following parameters: bAR density, G-coupled receptor kinases 2 and 5, stimulatory and inhibitory G-proteins, phosphorylation of myofilament targets of PKA, protein phosphatase 1, phospholamban, SERCA2a and single myocyte contractility. All parameters exhibited the expected alterations of heart failure, but for most of them the extent of alteration was greater in IDCM than in ISHD. Histological analysis also revealed higher collagen in IDCM compared to ISHD. Alterations in the bAR pathway are more pronounced in IDCM than in ISHD and may reflect sequential changes in cellular protein composition and function. Our data indicate that cellular dysfunction is more severe in IDCM than in ISHD.
Introduction
During increased cardiac stress stimulation of the b-adrenergic receptors (bAR) exerts a positive inotropic and lusitropic effect on the heart, via activation of protein kinase A (PKA)-mediated phosphorylation of Ca 2? -handling and contractile proteins (Bers 2002; Brodde and Michel. 1999; Kranias et al. 1985; Kentish et al. 2001; Zhang et al. 1995) . The positive inotropic effect largely originates from increased cytosolic [Ca 2? ] during the systolic phase of the cardiac cycle. The positive lusitropic effect results from increased cytosolic Ca 2? re-uptake into the sarcoplasmic reticulum, increased Ca 2? removal out of the cardiomyocyte, and desensitization of the myofilaments for Ca 2? . In patients with heart failure (HF) the sympathetic nervous system is chronically activated to maintain perfusion of vital organs via peripheral vasoconstriction and via an increase in heart rate and in myocardial contractility. Although aimed at maintaining cardiac pump function, chronic neurohumoral stimulation is detrimental for cardiac function and results in uncoupling and downregulation of mediators of the bAR pathway (Brodde and Michel 1999; Packer 1995) . Abnormalities in this pathway have been implicated as important determinants of diminished function of the failing human heart. The adverse effects of neurohumoral overstimulation is illustrated by the negative correlation between noradrenaline plasma levels and prognosis of the patients (Cohn et al. 1984) , and by the improvement of symptoms and prolonged survival of patients treated with b-blockers (Bohm and Maack 2000) . In line with reduced b-adrenergic signaling, previous studies in end-stage HF patients with idiopathic cardiomyopathy showed reduced PKA-mediated phosphorylation of downstream myofilament target proteins, cardiac myosin binding protein C (cMyBP-C) and troponin I (cTnI) (El-Armouche et al. 2007 ; van der Velden et al. 2003; Messer et al. 2007 Messer et al. , 2009 Copeland et al. 2010) , which coincided with increased myofilament Ca 2? -sensitivity (pCa 50 ). In patients with diastolic heart failure (i.e., HF with preserved ejection fraction, HFPEF) hypophosphorylation of titin has been associated with increased cardiomyocyte stiffness (F passive ) (Borbély et al. 2009 ). Insight in the modifications of the b-adrenergic pathway and coincident changes in cardiomyocyte function is needed to develop targeted therapy in HF patients. In a recent study we reported diverse changes at the myocardial ultrastructural level with prominent cardiomyocyte hypertrophy in HFPEF patients and low myofibrillar density in HF patients with reduced EF (HFREF) (van Heerebeek et al. 2006) . Moreover, F passive was higher in HFPEF than in HFREF. These cellular differences may alter responsiveness to current HF treatment, which includes b-blocker therapy. Likewise, patients with idiopathic (IDCM) and ischemic (ISHD) cardiomyopathy may show diverse cellular changes.
Although many studies investigated mediators of the bAR signaling pathway and sarcomeric function in human heart failure, a direct comparative investigation of both in samples from IDCM and ISHD patients is lacking. Within the present study a systematic analysis was performed from the bAR to sarcomeric protein composition and function in IDCM and ISHD patients, and compared to non-failing donor myocardium (donor). Radioligand binding studies were performed to determine bAR density. Protein analysis included down-stream components of the adrenergic signalling cascade, the phospho-proteome of the myofilaments, and SERCA2a and phospholamban levels. Myofilament function was determined in permeabilized single cardiomyocytes. Histological analysis included cardiomyocyte diameter, collagen volume fraction and myofibrillar density.
Methods

Human ventricular tissue
Left ventricular (LV) tissue samples were obtained during heart transplantation surgery from end-stage HF patients (NYHA III-IV) with IDCM (n = 13; 10 males, 3 females; mean age 51 ± 2 years) or ISHD (n = 10; 7 males, 3 females; mean age 51 ± 2 years)( Table 1) . Patients were classified to idiopathic dilated cardiomyopathy when the heart showed LV dilatation and LV systolic dysfunction with no identifiable cause and in the absence of coronary artery disease, hypertension, valvular disease and congenital heart disease sufficient to cause the observed myocardial abnormality (Elliott et al. 2008) . In contrast, patients with ischemic heart disease had a history of myocardial infarction and explanted hearts showed severe coronary artery disease upon pathologic inspection. Medication included angiotension-converting-enzyme inhibitors, angiotensin II receptor antagonists, diuretics, b-blockers, digoxin and anti-arrhythmic agents and did not differ between the IDCM and ISHD group. Tissue from 10 donor hearts (Table 1 ; 8 males, 2 females; mean age 38 ± 6 years) served as reference for non-failing myocardium. The tissue was collected in cardioplegic solution and stored in liquid nitrogen. Samples were obtained after informed consent and with approval of the local Ethical Committee (St Vincents' Hospital Human Research Ethics Committee, Sydney, Australia: File number: H03/118; Title: Molecular Analysis of Human Heart Failure). The investigation conforms with the principles outlined in the Declaration of Helsinki (1997).
Protein analysis
Radioligand binding
Tissue samples (~200 mg wet weight) were thawed in icecold 1 mM KHCO 3 solution, minced with scissors and then homogenized with an Ultra-Turrax (Janke & Kunkel, Staufen, Germany) for 10 s at maximum speed followed by twice 20 s at 2/3 of maximum speed. The homogenates were centrifuged for 15 min at 2509g and 4°C. The supernatant was filtered through medical gauze and centrifuged for 20 min at 50,0009g at 4°C. The sediment was resuspended in binding buffer (10 mM Tris, 154 mM NaCl, pH 7.4). Protein content was measured by the method of Bradford using bovine IgG as standard. Radioligand binding was performed as described earlier (Niclauss et al. 2006 ) using a 90 min incubation at 37°C with [ 125 I]iodocyanopindolol (ICYP; specific activity 2200 Ci/mmol, Perkin Elmer, Zaventem, Belgium) in a total volume of 250 ll. Non-specific binding was defined as binding in the presence of 100 lM isoproterenol (Sigma-Aldrich). All experiments were performed in duplicates in 96 well plates, and incubations were terminated by rapid vacuum filtration over Whatman GF/C using a Filtermate harvester (Perkin Elmer). Each filter was washed with approximately 10 ml of buffer. Radioactivity adherent to the filters was quantified in a Topcount NXT (Perkin Elmer) using Microsint O scintillator (Perkin Elmer). To determine the relative amount of b 1 AR and b 2 AR, membranes were incubated with ICYP (100 pM) in the presence or absence of eight concentrations (range
10
-10 to 10 -3 M) of the highly selective
Components of the b-adrenergic receptor pathway
Protein expression levels of G-coupled receptor kinases (GRK2 and GRK5), G-proteins (G s and G i ) and protein phosphatase 1 (PP-1) were analyzed by one-dimensional 15% SDS-polyacrylamide gel electrophoresis (1D-PAGE) and subsequent Western blotting. Samples were applied in 
Myofilament protein phosphorylation
Myofilament protein phosphorylation was determined using Pro-Q Diamond Phosphoprotein Stain as described previously (Zaremba et al. 2007 ). To preserve the endogenous phosphorylation status, frozen biopsies were homogenized in liquid nitrogen and re-suspended in 1 ml cold 10% trichloroacetic acid solution (TCA; dissolved in acetone containing 0.1% (w/v) dithiothreitol (DTT)). TCAtreated tissue pellets were homogenized in sample buffer containing 15% glycerol, 62.5 mM Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v) DTT. Tissue samples were separated on gradient gels (Criterion tris-HCl 4-15% gel, BioRad) and proteins were stained for one hour with Pro-Q Diamond Phosphoprotein Stain. Fixation, washing and de-staining were performed according to the manufacturer's guidelines (Molecular Probes). To assess protein content subsequently gels were stained overnight with SYPRO Ruby stain (Molecular Probes). Phosphorylation status of myofilament proteins was expressed relative to protein expression of cMyBP-C to correct for differences in sample loading. Staining was visualized using the LAS-3000 Image Reader and signals were analyzed with AIDA. Cardiac troponin I phosphorylation at PKA sites Ser 23/ 24 was detected with a primary rabbit polyclonal antibody (dilution 1:500; Cell signaling) in Western blotting. In addition, the recently developed Phos-tag TM acrylamide (FMS Laboratory; Hiroshima University, Japan) (Kinoshota et al. 2006 ) was used to visualize phosphorylated cTnI species using alkoxide-bridged dinuclear metal (Mn 2? ) complex as phosphate-binding tag (Phos-tag) molecule. Mn 2? -Phos-tag molecules preferentially capture phosphomonoester dianions bound to Ser, Thr and Tyr residues. Non-phosphorylated and phosphorylated cTnI species were separated in 1D-PAGE with polyacrylamidebound Mn 2? -Phos-tag and transferred to Western blots. Phosphorylated cTnI species in the gel are visualized as slower migration bands compared to the corresponding dephosphorylated cTnI form (Kooij et al. 2010; Messer et al. 2009 ).
SERCA2a and phospholamban
SERCA2a protein levels were determined immunochemically by dot-blot analysis, as described before, with minor modifications (Muller et al. 1991) . Briefly, homogenized tissue samples (typically 0.5 lg total protein) were spotted in triplo onto a nitrocellulose membrane. The blot was then incubated with a 1:2500 dilution of a polyclonal antiserum to SERCA2a and subsequently with 125I-labeled antirabbit immunoglobulin G (0.05 mg/ml, specific activity 7 mCi/mg). To detect phospholamban, blots were first incubated with a 1:2500 dilution of a monoclonal anti mouse antibody (Affinity Bioreagents) and subsequently with 125I-labeled anti-mouse immunoglobulin G. Blots were exposed to Phosphor Imager screens, which were then scanned and spots were quantified using ImageQuant software (Molecular Dynamics). All protein values for ISHD and IDCM samples were normalized to the average value observed in donor, which was set to 1.
Force measurements in single cardiomyocytes
Force measurements were performed in single, mechanically isolated cardiomyocytes as described previously (Kooij et al. 2010; van der Velden et al. 2003) . Tissue samples were defrosted in relaxing solution (in mmol/l: free Mg, 1; KCl, 145; EGTA, 2; MgATP, 4; imidazole, 10; pH 7.0), mechanically disrupted and incubated for 5 min in relaxing solution supplemented with 0.5% Triton X-100 to remove all membrane structures. Subsequently, cells were washed twice in relaxing solution, after which single cardiomyocytes were attached with silicone adhesive between a force transducer and a motor. Sarcomere length of isolated cardiomyocytes was adjusted to 2.2 lm. The pCa (-10 log[Ca 2? ]) ranged from 9.0 (relaxation solution) to 4.5 (maximal activation). All force values were normalized for cardiomyocyte cross-sectional area. Exposure to a series of solutions with intermediate pCa values (pCa 6.0-5.0) yielded the baseline force-pCa relation. On transfer of the cardiomyocyte from relaxing to activating solution, isometric force started to develop. Once a steady state force level was reached, the cell was shortened within 1 ms to 80% of its original length to determine the baseline of the force transducer. The distance between the baseline and the steady force level is the total force (F total ). After 20 ms, the cell was restretched and returned to the relaxing solution, in which a second slack test, of 10 s duration was performed to determine passive force (F passive ). Active force was obtained by subtracting passive force from the total force, i.e., F active = F total -F passive .
Quantitative histomorphometry Histomorphologic analysis of tissues was performed on elastica-von-Giesson and hematoxylin-eosin-stained 4 lm thick sections of tissue fixed in 5% formalin (Borbély et al. 2005) . Images of these sections were acquired using a projection microscope (950). Subsequent image analysis, using SlidebookTM 4.0 software (3I, Denver, Co), was performed to determine cardiomyocyte diameter and the extent of interstitial fibrosis, which was expressed as collagen volume fraction. Areas of reparative and perivascular fibrosis were excluded. Cardiomyocyte diameter was determined perpendicularly to the outer contour of the cell membrane at nucleus level in 15 representative myocytes of the cardiac tissue section, and collagen volume fraction was calculated as the sum of all connective tissue areas divided by the sum of all connective tissue and muscle areas averaged over 4-6 representative fields of the cardiac tissue section. Data were averaged per heart sample and averaged to obtain the mean of the group. For analysis of cardiomyocyte diameter and collagen volume fraction 9 ISHD, 7 IDCM and 5 donor hearts were included.
Analysis of myofibrillar density was performed in 8 ISHD, 6 IDCM and 5 donor hearts. Tissues samples were fixed in 2% (v/v) gluteraldehyde for 30 min and 1.5% (w/v) osmium tetroxide for 10 min dehydrated with acetone and embedded in Epon812. Ultrathin sections were collected on 300-mesh Formavar-coated Nickel-grids. The sections were contrasted with uranyl acetate and lead citrate and were examined in a Jeol-1200EX electron microscope. Quantitative analysis was performed with the above mentioned automated image analyzer. Cardiomyocyte myofibrillar density was calculated from the sum of the myofibrillar areas related to total cellular area in 4-6 representative myocytes per sample. Data were averaged per heart.
Data analysis
Competition binding data were analyzed by fitting monoand biphasic sigmoidal functions to the experimental data; a biphasic fit was accepted only if it resulted in a significant improvement as judged by an F-test. Resulting IC 50 values for the high and low affinity component of inhibition were converted to K i values based upon the Cheng-Prusoff equation (Cheng and Prusoff 1973) and assuming a K d value of ICYP of 72 pM (n = 4). Due to limited tissue availability, receptor density (B max ) was estimated based upon the specific binding (SB) of the single radioligand concentration (L) in the competition experiments relative to its K d using the equation B max = SB/(1 -1/(L/ K d ? 1)). The statistical significance of inter-group differences was assessed by one-way ANOVA followed by Dunnett's post-hoc tests.
Values are given as mean ± SEM of n observations. The mean data values of protein and histological analysis and force measurements in ISHD, IDCM and donor samples were compared using one-way ANOVA and Bonferroni-post tests. P \ 0.05 was considered significant. All statistical analysis was performed with Prism (version 4.01, Graphpad Software, San Diego, CA, USA).
Results
Components of the b-adrenergic receptor pathway
In all cases except one competition by the highly b 1 -selective antagonist CGP 20712A resulted in biphasic curves (Fig. 1a) . The -log K i values for high and low affinity sites, which identify b 1 AR and b 2 AR, respectively, were not significantly different between IDCM (8 hearts; 8.21 ± 0.19 and 5.59 ± 0.09) and ISHD (8 hearts; 8.17 ± 0.09 and 5.62 ± 0.10) myocardium, and did not differ from the values observed in donor (7 hearts; 8.55 ± 0.12 and 5.74 ± 0.11). Single point estimates of total bAR density, revealed significantly reduced bAR density in IDCM compared to donor, while the value observed in ISHD was intermediate between IDCM and donor (Fig. 1b) . The percentage of b 1 ARs did not differ between IDCM (50 ± 4%) and ISHD (47 ± 9%) samples and was comparable to the value observed in donor (52 ± 6%).
No difference was found in expression of GRK2 between IDCM and ISHD, while GRK5 was significantly higher in ISHD than in IDCM myocardium (Table 2) . Compared to donor GRK2 was significantly lower in both failing groups, while GRK5 was significantly higher in the ISHD group. G s expression did not differ between ISHD and IDCM, though was significantly lower in both failing groups compared to donor ( Fig. 1c; Table 2) . In addition to G s , we have analyzed three isoforms of inhibitory G-protein: G ia-1 , G ia-2 and G ia-3 . The heterotrimeric G-proteins are composed of a, b and c subunits, of which the a-subunit confers specificity to the G-protein (Wang and Dhalla 2000) . G ia-1 expression was significantly higher in IDCM than in ISHD and donor (Fig. 1d) , while G ia-2 was significantly higher in both failing groups compared to donor ( Table 2 ).The G ia-3 expression level was not altered in patient groups (data are summarized in Table 2 ).
Myofilament and calcium handling proteins
ProQ Diamond phosphostaining was used to detect phosphorylation of myofilament proteins. Figure 2a shows ProQ Diamond-stained cardiac samples from ISHD, donor (D) and IDCM myocardium separated on a gradient gel. The same gel was subsequently stained with SYPRO Ruby for analysis of total protein content (Fig. 2b) . The ProQ Diamond stained gel shows lower endogenous phosphorylation of the PKA-target proteins cMyBP-C and cTnI in failing compared to -donor. Noteworthy, cTnI phosphorylation was significantly higher in ISHD compared to IDCM (Fig. 2c) . In addition, phosphorylation of cMyBP-C was higher in ISHD compared to IDCM, though not significantly (P = 0.07). When the failing and donor were combined, a monovariate linear regression analysis revealed significant correlations between the ProQ Diamond-assessed phosphorylation status of cMyBPC and cTnI (P \ 0.0001; R 2 = 0.75) (Fig. 2d ). Higher PKA-mediated phosphorylation of cTnI (at Ser23 and Ser24, i.e., PKA sites) in ISHD compared to IDCM was confirmed in Western blotting (Fig. 3) . Consistent with ProQ Diamond analysis of cTnI phosphorylation, the Western blots revealed significantly lower cTnI phosphorylation at PKA-sites in failing compared to donor.
Analysis of cTnI species separated by Phos-tag polyacrylamide gels revealed three bands upon staining of Western blots with a specific anti-cTnI antibody (8I-7) in donor, while only two bands were observed in the failing sample shown in Fig. 4a . The lower band was recognized by an antibody directed against cTnI unphosphorylated at PKA sites (22B11). The upper band was recognized by the phosphorylation-specific antibody which recognizes the PKA-sites Ser 23 and Ser 24. The second band on the blot is the mono-phosphorylated form of cTnI (Messer et al. 2009 Fig. 1 All signals in IDCM and ISHD samples were normalized to the averaged value observed in donor, which was set to 1. GRK G-coupled receptor kinase, Gs G-stimulatory, Gi G-inhibitory, MLC-2P phosphorylated myosin light chain 2, PP-1 protein phosphatase 1. a.u. arbitrary units, n number of heart samples. * P \ 0.05 in Bonferronipost tests, IDCM versus ISHD; # P \ 0.05, in Bonferroni-post tests, failing versus donor shown in Fig. 4b . The distribution of the cTnI forms was significantly different among the three groups (Fig. 4c) . The unphosphorylated form was highest in IDCM, while the bisphosphorylated form was highest in donor. A significant correlation was observed between phosphorylated cTnI on Phos-tag and cTnI phosphorylation analyzed by ProQ Diamond ( Fig. 4d ; P \ 0.0001; R 2 = 0.75). ProQ Diamond analysis also revealed higher phosphorylation of myosin light chain 2 (MLC-2) in ISHD compared to both IDCM and donor (Table 2) , while there were no significant differences in phosphorylation of the other myofilament proteins, desmin and troponin T (data not shown). The difference in MLC-2 phosphorylation may be in part explained by differences in PP-1 expression. Western blot analysis of PP-1 revealed significantly higher PP-1 expression in IDCM compared to ISHD and donor (Table 2) .
Western blot analysis showed increased phospholamban protein levels in IDCM and ISHD compared to donor and a significantly lower SERCA2a level in IDCM compared to both ISHD and donor ( Table 2 ). The ratio of phospholamban over SERCA2a significantly differed among groups and was highest in IDCM. Higher Ca 2? -sensitivity in IDCM than in ISHD Force measurements were performed in single cardiomyocytes isolated from 8 IDCM hearts (42 cardiomyocytes), 8 ISHD hearts (27 cardiomyocytes) and 8 donor hearts (41 cardiomyocytes). Cross-sectional area of the cardiomyocytes determined at a sarcomere length of 2.2 lm was significantly higher in IDCM (556 ± 44 lm 2 ) and ISHD (690 ± 75 lm 2 ) compared to donor (339 ± 26 lm 2 ) (P \ 0.05 in one-way ANOVA). Maximal active tension (F active ) did not differ (Fig. 5a) , while passive tension (F passive ) was significantly lower in IDCM and ISHD compared to donor (Fig. 5b) . Noteworthy, myofilament pCa 50 was significantly lower in ISHD compared to IDCM (Fig. 5c, d) . A significantly higher pCa 50 was found in failing heart compared to donor (Fig. 5c, d) . Moreover, the steepness of the sigmoidal force-pCa relationship (nHill) was significantly higher in ISHD (4.05 ± 0.12) compared to IDCM (3.58 ± 0.10) and donor (3.70 ± 0.14). A monovariate linear regression analysis revealed a significant correlation between pCa 50 and phosphorylated cMyBP-C (P \ 0.05; R 2 = 0.24) (Fig. 5e) , while no significant correlation was found between pCa 50 and ProQ Diamond-analyzed phosphorylated cTnI (P = 0.09; R 2 = 0.12). Troponin I phosphorylation determined by Phos-tag analysis did significantly Fig. 4 a Phos-tag analysis of troponin I (cTnI) species revealed three cTnI bands in donor, of which the lowest band stained with an antibody directed against nonphosphorylated cTnI (22B11), and the highest band stained with the antibody specific for cTnI phosphorylation at PKA sites Ser23 and Ser24. b Examples of cTnI species separated by Phos-tag analysis in different ISHD, IDCM and donor samples. c The distribution of cTnI species was significantly different among groups. d A significant correlation was observed between phosphorylated cTnI on Phos-tag and phosphorylated cTnI on Pro-Q Diamond-Stain (P \ 0.0001; R 2 = 0.75).
# P \ 0.05, in Bonferroni-post tests, failing versus donor correlate with pCa 50 (P \ 0.01; R 2 = 0.43) (Fig. 5f ). The individual data per patient/donor for phosphorylation of the PKA target proteins, cMyBP-C and cTnI, and myofilament Ca 2? -sensitivity are summarized in Table 1 .
Structural alterations
Representative examples of light microscopy and electron microscopy images of LV sections from the three groups are shown in Fig. 6a and b, respectively. Cardiomyocyte diameter did not differ between ISHD and IDCM, but was significantly higher than observed in donor (Fig. 6c) . Collagen volume fraction was significantly higher in IDCM compared to ISHD. Moreover, collagen volume fraction was significantly higher in both failing compared to donor (Fig. 6d) . No differences were found in myofibrillar density between ISHD and IDCM, while it was significantly lower in both failing compared to donor (Fig. 6e) .
Discussion
In the present study, diverse changes were found in the bAR pathway in IDCM and ISHD patients. The results indicate that there are differences in the cellular structure and function between both patient groups. Compared to ISHD, IDCM was characterized by a more severe receptor bAR down-regulation and increased G i expression, increased PP-1 expression, an enhanced reduction in protein phosphorylation, increased myofilament pCa 50 , reduced SERCA2a expression and higher collagen volume fraction. The data indicate that cellular dysfunction is more severe in IDCM than in ISHD patients.
Changes in components of the b-adrenergic pathway
In the present study, total bAR density was significantly reduced in IDCM compared to donor with intermediate cTnI-P (mol P/mol total cTnI) pCa 50 C Fig. 5 a F active did not differ among groups. b F passive was significantly lower in failing groups compared to donor. c, d pCa 50 was significantly higher in failing groups compared to donor. The pCa 50 was significantly lower in ISHD compared to IDCM. e A significant correlation was observed between pCa 50 and phosphorylated cMyBP-C (P \ 0.05; R 2 = 0.24). f A significant correlation was also found between pCa 50 and Phos-tag analyzed cTnI phosphorylation (P \ 0.01; R 2 = 0.43). *P \ 0.05 in Bonferroni-post tests, IDCM versus ISHD; values in ISHD. This down-regulation may have been caused by reduced mRNA levels (Hadcock and Malbon 1998) . In addition, bAR may be degraded upon internalization of receptors, which is preceded by the process of receptor uncoupling (Wang and Dhalla 2000) . The regulating step in the latter process is receptor phosphorylation, either by second-messenger activated kinases such as PKA, or by GRKs, which only phosphorylate agonist occupied receptors (Fig. 7) . Both GRK2 and GRK5 are determinants of bAR responsiveness of the heart, as they disrupt the interaction between receptors and the heterotrimeric G proteins (Wang and Dhalla 2000) . This process of receptor uncoupling is thought to be an important contributor to bAR desensitization and down-regulation due to increased sympathetic tone in cardiac disease. In failing human tissue, Ungerer et al. (1993 Ungerer et al. ( , 1994 showed increased GRK2 mRNA and activity in both ISHD and IDCM. In contrast, in the present study we observed lower GRK2 protein expression in both failing groups compared to donor, while GRK5 protein expression was significantly higher in ISHD compared to IDCM and donor.
The discrepant observation in GRK5 between ISHD and IDCM may reflect a difference in severity of disease, as Leineweber et al. (2005) observed an increase in GRK activity in right atrial tissue from patients at NYHA I and II, while in more severe stages (NYHA III and IV) GRK activity was similar as observed in controls. Interestingly, bAR density did not differ in NYHA I and II and was significantly reduced compared to controls in NYHA III and IV. These data are suggestive for a transient increase in GRK activity during the course of heart failure, and indicate that increases in GRK precede receptor down-regulation in the human heart. Accordingly, the high GRK5 expression and the lower reduction in bAR density in ISHD compared to IDCM observed in the present study may reflect a less severe disease stage in ISHD, despite similar NYHA classification. The latter is further supported by the significantly higher expression of inhibitor G-protein in IDCM compared to ISHD.
More severe cellular phenotype in IDCM compared to ISHD Analysis of sarcomeric protein phosphorylation revealed significant differences in the bAR target proteins cMyBP-C and cTnI. Consistent with previous studies (El-Armouche et al. 2007; van der Velden et al. 2003; Messer et al. 2007 Messer et al. , 2009 Copeland et al. 2010 ) phosphorylation of cMyBP-C and cTnI was significantly lower in both failing groups compared to donor, which has been explained by reduced PKA-mediated phosphorylation due to bAR desensitization and down-regulation in cardiac disease (Wolff et al. 1996; van der Velden et al. 2003) . Noteworthy, cMyBP-C and cTnI phosphorylation was lower in IDCM compared to ISHD, which fits the larger reduction in bAR density and larger increase in G ai-1 expression observed in IDCM compared to ISHD. The higher myofilament pCa 50 in IDCM compared to ISHD may be well explained by the significantly lower (PKA-mediated) myofilament protein phosphorylation observed in IDCM.
Interestingly, analysis of cTnI species using Phos-tag polyacrylamide gels showed that the difference in cTnI phosphorylation between IDCM and donor can be largely explained by a difference in the bis-phosphorylated form of cTnI (Fig. 4c) . It is tempting to speculate that a difference in cTnI phosphorylation at PKA sites Ser 23/24 underlies the differences in pCa 50 among groups. Although a significant correlation was found between myofilament pCa 50 and phosphorylation status of cMyBP-C (Fig. 5e ), the correlation with ProQ Diamond assessed cTnI phosphorylation did not reach statistical significance (P = 0.09). Noteworthy, cTnI phosphorylation determined with the Phos-tag assay did significantly correlate with myofilament Ca 2? -sensitivity ( Fig. 5f ), indicating that Phos-tag analysis is a very accurate method to determine cTnI phosphorylation.
The correlation between cMyBP-C phosphorylation and pCa 50 was stronger when cMyBP-C phosphorylation was combined with ProQ-Diamond assessed cTnI phosphorylation (P = \0.05; R 2 = 0.27; not shown). In a recent study in human myocardium we showed that myofibrillar targets of PKA, cMyBP-C and/or titin, play an important role in modulating the effect of cTnI phosphorylation on pCa 50 in human myocardium (Kooij et al. 2010) . Exchange of endogenous (mostly unphosphorylated) cTnI with PKAphosphorylated troponin complex did not reduce pCa 50 in failing cardiomyocytes, in which endogenous cMyBP-C phosphorylation is low. Accordingly, our present data are compatible with a modulatory role for cMyBP-C in force development at submaximal calcium concentrations in human myocardium.
In addition to the PKA targets, cTnI and cMyBP-C, phosphorylation of MLC-2 was significantly lower in IDCM than in ISHD. Dephosphorylation of MLC-2 occurs via PP-1, which was significantly higher in IDCM compared to ISHD. Although increased PP-1 expression may explain the relatively low MLC-2 phosphorylation in IDCM, it cannot explain the significantly lower MLC-2 phosphorylation in donor compared to ISHD, as PP-1 expression tended to be even lower in donor compared to ISHD. Other kinases/phosphatases most likely underlie the differences in MLC-2 phosphorylation observed between ISHD and donor myocardium and warrant future research.
Moreover, upon activation of bAR, PP-1 activity is depressed by PKA via phosphorylation of protein inhibitor 1 (I1) (Neumann et al. 1991) . Thus, apart from increased PP-1 expression, perturbations in bAR signaling will increase activity of PP-1, which may explain the lower MLC-2 phosphorylation in IDCM compared to Overall, changes were more severe in IDCM compared to ISHD, indicated by the dotted arrows, i.e., decrease or increase in IDCM compared to ISHD. P Phosphorylation, bAR b-adrenergic receptor, Gs G-stimulatory protein, Gi G-inhibitory protein, GRK G-coupled receptor kinase, Ca 2? calcium, ATP adenosine tri-phosphate, cAMP cyclic AMP, PKA Protein kinase A, PP-1 protein phosphatase 1, MLC-2 myosin light chain 2, cMyBP-C cardiac myosin binding protein C, cTnI cardiac troponin I, SERCA2a SR Ca 2? ATPase ISHD. Increased activity and mRNA level of PP-1 has been reported previously in human IDCM (Neumann et al. 1997) . Increased activity of PP-1 in a transgenic mouse model resulted in decreased myocardial contractility and dilated cardiomyopathy underscoring a detrimental role for PP-1 in heart failure (Carr et al. 2002) . Increased PP-1 will also impair Ca 2? -handling by dephosphorylation of phospholamban. The resulting reduction in SR Ca 2? loading will be enhanced further by the reduction in SERCA2a expression in IDCM. Although several studies did not find differences in SERCA2a and PLB at mRNA levels between ISHD and IDCM (Arai et al. 1993; Flesch et al. 1996) , our study showed reduced SERCA2a protein expression in IDCM, and increased phospholamban expression in both failing groups. Higher PP-1 expression and lower SERCA2a expression are indicative for a more severe cellular phenotype in patients with IDCM.
In line with previous studies (Anversa et al. 1986; Parodi et al. 1993; Weber 1989) we observed three structural alterations in end-stage heart failure: increased cardiomyocyte diameter (Fig. 6c) , increased collagen volume fraction (Fig. 6d ) and decreased myofibrillar density (Fig. 6e ). While no difference was found in cardiomyocyte diameter and myofibrillar density between IDCM and ISHD, collagen volume fraction was significantly higher in IDCM compared to ISHD, which is in line with a previous study by Parodi et al. (1993) .
Adaptive cellular mechanism
In agreement with previous studies (Makarenko et al. 2004; Nagueh et al. 2004; Neagoe et al. 2002 ) F passive in end-stage human heart failure was lower in comparison to donor. It has been proposed that the reduction in F passive is due to a shift in titin isoform composition, from the stiff N2B to the more compliant N2BA isoform (Makarenko et al. 2004; Nagueh et al. 2004) . In contrast, enhanced F passive was found in patients with less severe forms of heart failure (NYHA II-III) (Borbély et al. 2005 (Borbély et al. , 2009 van Heerebeek et al. 2006) , in which a similar shift in titin isoform composition was found as observed in endstage heart failure (i.e., more compliant isoform). The increased F passive at an early phase of heart failure was related with relative hypophosphorylation of the stiff N2B titin isoform (Borbély et al. 2009 ). Cardiomyocyte stiffness reflects the balance between isoform composition and isoform-specific phosphorylation status of titin. The shift to the compliant N2BA isoform during heart failure seems to be an adaptive mechanism to lower passive force (Makarenko et al. 2004) , which may be maximal at end-stage heart failure.
Conclusions
Comparison of myocardium from patients with ISHD and IDCM end-stage HF revealed more severe cellular perturbations in patients with IDCM which are summarized in Fig. 7 . Our data support previous studies in which transient changes were observed in the bAR pathway. Increased GRK expression may be a primary event and possibly precedes the reduction in bAR density, and the changes in expression of proteins involved in calcium handling and PP1. Noteworthy, Leineweber et al. (2005) showed that GRK5 was significantly lower in patients treated with b-blockers only in the relatively early stages of heart failure (i.e., NYHA I and II), in which GRK5 was higher compared to the end-stage of HF. Hence, the response to current treatment may depend on cause of cardiac disease, and may be less in patients with IDCM.
